Clinical trial · Interventional
Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)
NCT06367751CI-TRIAL-00105221LIQPLATactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to assess the implementation and feasibility of ctDNA measurements from blood samples obtained during routine clinical care of cancer patients in the University Hospital Basel. Researchers will compare clinical and patient reported outcomes from the LIQPLAT study with patients who did not receive ctDNA measurements (external comparator from registry AO\_2023-00091). Blood samples will be drawn from the patients as part of routine care and ctDNA measurements will be performed on these samples.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ctDNA measurement | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Active Comparator
- description
- Patients included in the ongoing registry AO\_2023-00091. Patients will have ctDNA measurements being performed on blood samples collected as part of clinical routine.
- interventionNames
- Diagnostic Test: ctDNA measurement
Primary outcomes (4)
- measure
- Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment
- timeFrame
- 1 time assessment at baseline
- description
- Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment. Calculated as the number of patients with detectable ctDNA over the total number of patients included, expressed as a percentage.
- measure
- Patients in whom actionable alterations were identified in ctDNA analysis
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a proven solid malignant disease, i.e. with solid malignant tumors where no primary surgical resection is planned OR solid malignant tumors that are locally advanced and inoperable OR solid tumors that are metastatic * No prior treatment for advanced/metastatic disease * Indication for medical anti-cancer treatment (including combined chemoradiotherapy) as judged by the treating physician * Patient age 18 years and older * General research consent of the University Hospital Basel Exclusion Criteria: ● Patients with primary brain tumors
References
Publications (1)
- DERIVEDSchwenke JM, Schmitt AM, McLennan S, Janiaud P, Laubli H, Binder M, Alborelli I, Matter MS, Hinke J, Widmer CC, Hemkens LG, Kasenda B, Briel M. Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trial. BMJ Open. 2025 Oct 28;15(10):e100537. doi: 10.1136/bmjopen-2025-100537. PMID 41151945